期刊文献+

吗替麦考酚酯对肺动脉高压大鼠血管结构及细胞因子和受体的影响 被引量:3

Effect of mycophenolate mofetil on vascular structure and cytokines and receptors of rat with pulmonary arterial hypertension
原文传递
导出
摘要 目的观察吗替麦考酚酯对野百合碱诱导的肺动脉高压(PAH)大鼠肺动脉压力、碱性成纤维细胞生长因子(bFGF)、内皮素-1及受体的影响。方法建立野百合碱诱导的PAH大鼠模型。分为4组:正常对照组;野百合碱组;低剂量治疗组;高剂量治疗组,每组各8只。通过Masson染色显示肺泡内动脉血管壁肌化情况;测定收缩期肺动脉压力(SPAP)、右心室肥厚指数(RVI)、血清及肺匀浆中bFGF和受体、肺匀浆中内皮素-1及受体水平,各组间差异采用方差分析及q检验,方差不齐采用秩和检验。结果①高、低剂量治疗组与野百合碱组相比,SPAP[(40±13),(53+10)与(68±10)mmHg]及RVI(0.36±0.06,0.38±0.03与0.44±0.05)均降低(P〈0.05);②高、低剂量治疗组与野百合碱组相比,血清bFGF均降低[(2.3±1.9),(2.7±1.3)与(6.9±5.4)pg/ml,P〈0.05];③高、低剂量治疗组与野百合碱组相比,肺泡内动脉血管壁肌化程度改善及肺小血管中肌性动脉数量减少。结论吗替麦考酚酯抑制血管肌化、降低SPAP和RVI,其机制可能通过抑制bFGF、内皮素-1及受体的表达抑制平滑肌增殖,从而达到缓解PAH。 Objective To observe the effect of mycophenolate mofetil (MMF) on systolic pulmonary arterial pressure (SPAP), right ventricle index (RVI), cytokiues, receptors of pulmonary artery hypertension (PAH) rat models. Methods The rat models of monocrotaline (MCT)-PAH were developed. Thirty-two Sprague-Dawley male rats were divided randomly into four groups: the control group, the MCT, the MCT + low-dose MMF (20 mg·kg^-1·d^-1, MMF 20) and the MCT + high-dose MMF (40 mg·kg^-1·d^-1, MMF 40). There were eight rats in each group. SPAP, RVI, cytokines and receptor in the serum and lung tissue were measured in all rats. Comparisons between multiple groups were performed with q test and rank sum test. Results (1) Low-dose and high-dose MMF group were compared with the MCT group, SPAP [(40±13), (53±10) vs (68±10) mm Hg] and RVI (0.36±0.06, 0.38+0.03 vs 0.44±0.05) were reduced and showed statistically significant difference respectively (P〈0.05). (2) Compared with the MCT group, basic fibroblast growth factor (bFGF) of serum in both low-dose and high-dose MMF group were reduced and showed statistical difference respectively [ (2.3±1.9), (2.7±1.3) vs (6.9±5.4) pg/ml, P〈0.05 ]. (3) Low-dose and high-dose MMF group were compared with the MCT group and showed that MA was decreased and the musculization of arterial wall was improved. Conclusion MMF can reduce SASP, RVI, number of MA. The inhibitory effect of MMF in PAH is possibly by inhibiting cytokines and receptors.
作者 张永锋 郑毅
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2011年第9期625-628,I0005,共5页 Chinese Journal of Rheumatology
基金 基金项目:国家自然科学基金(30872329)
关键词 高血压 肺性 细胞因子类 成纤维细胞生长因子2 吗替麦考酚酯 Hypertension, pulmonary Cytokines Fibroblast growth factor 2 Mycophenolate mofetil
  • 相关文献

参考文献18

  • 1Rubin LJ. Pulmonary arterial hypertension. Pulmonary arterial hypertension. Proc Am Thorac Soc, 2006, 3: 111-115.
  • 2Liu C, Liu K, Ji Z, et al. Treatments for pulmonary arterial hypertension. Respir Med, 2006, 100: 765-774.
  • 3叶文玲.霉酚酸酯药理作用的研究现状[J].国外医学(泌尿系统分册),1998,18(6):281-284. 被引量:9
  • 4Park J, Ha H, Seo J, et al. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am J Transplant, 2004, 4: 1982-1990.
  • 5Haug C, Schmid-Kotsas A, Linder T, et al.Influence of hepatocyte growth factor, epidermal growth factor, and mycophenolic acid on endothelin-1 synthesis in human endothelial cells. Nephrol Dial Transplant, 2001, 16: 2310-2316.
  • 6Sabuda-Widemann D, Grabensee B, Schwandt C, et al. Mycophenolic acid inhibits the autocrine PDGF-B synthesis and PDGF-BB-induced mRNA expression of Egr-1 in rat mesangial cells. Nephrol Dial Transplant, 2009, 24: 52-61.
  • 7Wu YG, Lin H, Qi XM, et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol, 2006, 6: 445-453.
  • 8Suzuki C, Takahashi M, Morimoto H, et al. Mycophenolate mofetil attenuates pulmonary" arterial hypertension in rats. Biochem Biophys Res Commun, 2006, 349: 781-788.
  • 9孙波 刘文利.右心导管测定大鼠肺动脉压的实验方法[J].中国医学科学院学报,1984,6:465-465.
  • 10Lipke DW, Arcot SS, Gillespie MN, et al. Temporal alterations in specific basement components in lungs from monocrotaline- treated rats. Am J Resper Cell Mol Biol, 1993, 9: 418-428.

二级参考文献38

  • 1[2]Becker BN. Mycophenolate mofetil[J]. Transplant Proc, 1999;31(5) :2777 - 8
  • 2[3]Ziswiler R, Steinmann-niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: a new approach to therapy of experimental mesangial proliferative glomerulonephritis [ J]. J Am Soc Nephrol, 1998;9(11) :2055 - 66
  • 3[5]Wahab NA, Weston BS, Robters T, Mason RM. Connective tissue growth factor and regulation of mesangial cell cycle: role in cellular hypertrophy[J]. J Am Soc Nephrol, 2002; 13 (10):2437 - 45
  • 4[6]Grotendorst GR. Connective tissue growth factor: a mediator of TGF- beta action on fibroblasts[J]. Cytokine Growth Factor Rev,1997;8(3): 171 - 9
  • 5[7]Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis [ J ]. J Am Soc Nephrol, 2000; 11(1):25-38
  • 6[8]Utimura R, Fujihara CK, Matter AL, Malheiros DM, Noronha IL, Zatz R, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes[J]. Kidney Int, 2003;63(1) :209 - 16
  • 7Farber HW,Loscalzo J.Pulmonary arterial hypertension.N Engl J Med,2004,351:1655-1665.
  • 8Puri A,McGoon MD,Kushwaha SS.Pulmonary arterial hypertension:current therapeutic strategies.Nat Clin Pract Cardiovasc Med,2007,4:319-329.
  • 9Traiger GL.Pulmonary arterial hypertension.Crit Care Nurs,2007,30:20-43.
  • 10Coghlan JG,Handler C.Connective tissue associated pulmonary arterial hypertension.Lupus,2006,15:138-142.

共引文献142

同被引文献24

  • 1王建军,钟前进,肖颖彬.低氧性肺动脉高压大鼠肺动脉和右心室重构研究[J].四川医学,2006,27(4):346-348. 被引量:4
  • 2孙波 刘文利.右心导管测定大鼠肺动脉压的实验方法[J].中国医学科学院学报,1984,6:465-465.
  • 3Grimminger F, Schermuly RT. PDGF receptor and its antago- nists: role in treatment of PAH[J]. Adv Exp Med Biol, 2010, 661 : 435-446.
  • 4Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease[J]. Prog Cardiovasc Dis, 2002, 45: 225-234.
  • 5Lipke DW, Arcot SS, Gillespie MN, et al. Temporal alterations in specific basement components in lungs from monocrotaline-treated rats[J]. Am J Resper Cell Mol Biol, 1993, 9: 418-428.
  • 6Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy[J]. Br Heart J, 1952, 14: 413-420.
  • 7Dhala A. Pulmonary arterial hypertension in systemic lupus ery- thematosus: current status and future direction[J]. Clin Dev Im- munol, 2012, 2012: 854941.
  • 8Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells[J]. Int J Clin Pharma- col Ther, 2003, 41: 465-469.
  • 9Suzuki C, Takahashi M, Morimoto H, et al. Myeophenolate mofetil attenuates pulmonary arterial hypertension in rats[J]. Bioehem Biophys Res Commun, 2006, 349: 781-788.
  • 10Ahn HI, Park J, Song JS, et al. Mycophenolie acid inhibits oleie acid induced vascular smooth muscle cell activation by inhibiting cellular reactive oxygen species[J]. Transplantation, 2007, 84: 634-638.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部